 U.S.
buys additional doses of Eli Lilly, Regeneron COVID-19 therapy
Send a link to a friend
[September 15, 2021]
(Reuters) -Eli Lilly and Company said on
Wednesday the U.S. government bought 388,000 additional doses of its
COVID-19 antibody therapy, as infections surge due to the fast-spreading
Delta variant.
|
|
 The news comes after Regeneron Pharmaceuticals Inc said late on
Tuesday the U.S. government was buying 1.4 million additional doses
of its COVID-19 antibody cocktail, REGEN-COV.
Lilly said its deal with the U.S government is expected to generate
approximately $330 million in revenue in the second half of 2021,
with about 200,000 doses expected to be shipped in the third quarter
this year and the remaining in fourth.
"The recent increase in COVID-19 cases has caused a substantial rise
in the utilization of monoclonal antibody drugs, particularly in
areas of the country with low vaccination rates," Lilly's chief
scientific and medical officer Daniel Skovronsky said.
[to top of second column] |
 The drugmaker will supply
additional doses of etesevimab to be paired with
doses of its other COVID-19 antibody therapy,
bamlanivimab, previously purchased by the U.S.
government.
Bamlanivimab and etesevimab are authorized for
use in people 12 years and above with
mild-to-moderate infection and at high risk for
progression to severe COVID-19.
(Reporting by Mrinalika Roy in Bengaluru;
Editing by Shinjini Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
